MARKET

KDMN

KDMN

Kadmon Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.73
-0.09
-1.02%
Closed 16:56 09/17 EDT
OPEN
8.79
PREV CLOSE
8.82
HIGH
8.86
LOW
8.73
VOLUME
9.53M
TURNOVER
--
52 WEEK HIGH
9.20
52 WEEK LOW
3.145
MARKET CAP
1.51B
P/E (TTM)
-13.1476
1D
5D
1M
3M
1Y
5Y
Mizuho Downgrades Kadmon Holdings to Neutral, Lowers Price Target to $9.5
Mizuho analyst Mara Goldstein downgrades Kadmon Holdings (NASDAQ:KDMN) from Buy to Neutral and lowers the price target from $13 to $9.5.
Benzinga · 5d ago
Wilson Disease Drugs Market: Trends, Key Players, Overview, Competitive Breakdown and Regional Forecast by 2029
Research Nester has released a report titled "" which delivers detailed overview of the global Wilson disease drugs market in terms of market segmentation by indication, drug type, end-user and by region.
AmericaNewsHour · 6d ago
UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9
MT Newswires · 09/10 12:58
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Zacks · 09/10 12:12
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
Zacks.com · 09/09 14:47
--Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger
MT Newswires · 09/09 13:34
10 Biggest Price Target Changes For Thursday
Telsey Advisory Group lifted the price target on Lululemon Athletica Inc. (NASDAQ: LULU) from $460 to $485. Lululemon shares surged 13.9% to $433.58 in pre-market trading.
Benzinga · 09/09 12:35
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Benzinga · 09/09 12:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDMN. Analyze the recent business situations of Kadmon Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDMN stock price target is 12.10 with a high estimate of 20.00 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 193
Institutional Holdings: 168.46M
% Owned: 97.19%
Shares Outstanding: 173.33M
TypeInstitutionsShares
Increased
45
8.90M
New
16
885.12K
Decreased
49
11.32M
Sold Out
16
1.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.39%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Tasos Konidaris
President/Chief Executive Officer/Director
Harlan Waksal
Chief Financial Officer/Executive Vice President
Steven Meehan
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gregory Moss
Executive Vice President
John Ryan
Senior Vice President
Simon Cooper
Independent Director
Eugene Bauer
Independent Director
David Cohen
Independent Director
Arthur Kirsch
Independent Director
Nancy Miller-Rich
Independent Director
Cynthia Schwalm
No Data
About KDMN
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Webull offers kinds of Kadmon Holdings Inc stock information, including NASDAQ:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDMN stock methods without spending real money on the virtual paper trading platform.